翰森制药(03692.HK) 公布,集团创新药阿美乐获国家药监局发的药品注册证书,批准增加用于含铂根治性放化疗后未出现疾病进展的不可切除的局部晚期表皮生长因子受体外显子19缺失或外显子21(L858R)置换突变的非小细胞肺癌患者的治疗适应症。此为阿美乐获批的第三项适应症。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-10 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.